Browsing Caprisa (Centre for the Aids programme of research in South Africa) by Title
Now showing items 310-329 of 448
-
Patients’ readiness to start highly active antiretroviral treatment for HIV.
(BMJ publishing group., 2005)Assessing whether patients are ready to start antiretroviral treatment may improve HIV prevention and treatment outcomes. -
Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.
(American Society for Microbiology., 2012)On the basis of positive preclinical data, we evaluated the safety and immunogenicity of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101), expressing a nonmyristoylated form of Gag, in two double-blind, randomized, ... -
Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.
(BioMed Central., 2018)Abstract available in pdf. -
A pilot study of once-daily antiretroviral therapy integrated with Tuberculosis directly observed therapy in a resource-limited setting.
(Lippincott Williams & Wilkins., 2003)To determine the feasibility and effectiveness of integrating highly active antiretroviral therapy (HAART) into existing tuberculosis directly observed therapy (TB/DOT) programs, we performed a pilot study in an urban ... -
Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression.
(Lippincott Williams & Wilkins., 2010)Background: Both T-cell activation during early HIV-1 infection and soluble markers of immune activation during chronic infection are predictive of HIV disease progression. Although the acute phase of HIV infection is ... -
Population pharmacokinetics and pharmacodynamics of Ofloxacin in South African patients with multidrug-resistant tuberculosis.
(American Society for Microbiology., 2012)Despite the important role of fluoroquinolones and the predominant use of ofloxacin for treating multidrug-resistant tuberculosis in South Africa, there are limited data on ofloxacin pharmacokinetics in patients with ... -
Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.
(American Association for the Advancement of Science., 2017)Abstract available in pdf. -
Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop.
(American Society for Microbiology., 2010)The targets of broadly cross-neutralizing (BCN) antibodies are of great interest in the HIV vaccine field. We have identified a subtype C HIV-1-superinfected individual, CAP256, with high-level BCN activity, and ... -
Preexposure prophylaxis for HIV prevention.
(Massachusetts Medical Society., 2012)No abstract available. -
Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa.
(Taylor & Francis., 2014)Abstract available in pdf. -
Pregnancies complicated by multidrug-resistant tuberculosis and HIV co-infection in Durban, South Africa.
(International Union against Tuberculosis and Lung Disease., 2006)SETTING: Tertiary hospitals in KwaZulu Natal, South Africa. OBJECTIVE: To study the impact of multidrug-resistant tuberculosis (MDR-TB) and human immunodeficiency virus-1 (HIV-1) co-infection during pregnancy on maternal ... -
Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women.
(Plos., 2011)Background: HIV prevention trials are increasingly being conducted in sub-Saharan Africa. Women at risk for HIV are also at risk of pregnancy. To maximize safety, women agree to avoid pregnancy during trials, yet pregnancies ... -
Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
(BioMed Central., 2007)Background. Few studies address the use of paediatric highly active antiretroviral therapy (HAART) in Africa. Methods. We performed a retrospective cohort study to investigate preliminary outcomes of all children eligible ... -
Preservation HIV-1–specific IFNg+ CD4+ T-Cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
(Lippincott Williams & Wilkins., 2011)Abstract: The Centre for the AIDS Program of Research in South Africa 004 trial demonstrated reduction of sexual HIV-1 acquisition in women using a vaginal microbicide containing tenofovir. A better understanding of the ... -
Prevalence and trends of staphylococcus aureus bacteraemia in hospitalized patients in South Africa, 2010 to 2012: laboratory-based surveillance mapping of antimicrobial resistance and molecular epidemiology.
(Public Library of Science., 2015)Abstract available in pdf. -
Prevalence of HIV, HSV-2 and pregnancy among high school students in rural KwaZulu-Natal, South Africa: a bio-behavioural cross-sectional survey.
(BMJ., 2014)Abstract available in pdf. -
Preventing HIV infection in women: A global health imperative.
(Oxford University Press on behalf of University of Chicago Press., 2010)Women account for approximately one-half of all human immunodeficiency virus (HIV) infections worldwide. Sexual transmission is the dominant mode of HIV transmission to women, and there is a concomitant associated epidemic ... -
Prevention of HIV by male circumcision : effective but integration with existing sexual health services remains the biggest challenge.
(BMJ Publishing Group., 2007)No abstract available. -
Prevention of HIV in adolescent girls and young women : key to an AIDS-free generation.
(Wolters Kluwer Health., 2017)Abstract available in pdf.